Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Cost-effective boosting allocations in the post-Omicron era of COVID-19 management

View ORCID ProfileThao P. Le, View ORCID ProfileEamon Conway, View ORCID ProfileEdifofon Akpan, View ORCID ProfileIsobel Abell, View ORCID ProfilePatrick Abraham, View ORCID ProfileChristopher M. Baker, View ORCID ProfilePatricia T. Campbell, View ORCID ProfileDeborah Cromer, View ORCID ProfileMichael J. Lydeamore, Yasmine McDonough, View ORCID ProfileIvo Mueller, View ORCID ProfileGerard Ryan, View ORCID ProfileCamelia Walker, Yingying Wang, View ORCID ProfileNatalie Carvalho, View ORCID ProfileJodie McVernon
doi: https://doi.org/10.1101/2023.11.14.23298536
Thao P. Le
aSchool of Mathematics and Statistics, The University of Melbourne, Melbourne, 3010, Victoria, Australia
bMelbourne Centre for Data Science, The University of Melbourne, Melbourne, 3010, Victoria, Australia
cCentre of Excellence for Biosecurity Risk Analysis, The University of Melbourne, Melbourne, 3010, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Thao P. Le
  • For correspondence: tk.le{at}unimelb.edu.au natalie.carvalho{at}unimelb.edu.au j.mcvernon{at}unimelb.edu.au
Eamon Conway
dPopulation Health & Immunity Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, 3052, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Eamon Conway
Edifofon Akpan
eMelbourne School of Population and Global Health, The University of Melbourne, Melbourne, 3010, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Edifofon Akpan
Isobel Abell
aSchool of Mathematics and Statistics, The University of Melbourne, Melbourne, 3010, Victoria, Australia
bMelbourne Centre for Data Science, The University of Melbourne, Melbourne, 3010, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Isobel Abell
Patrick Abraham
eMelbourne School of Population and Global Health, The University of Melbourne, Melbourne, 3010, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Patrick Abraham
Christopher M. Baker
aSchool of Mathematics and Statistics, The University of Melbourne, Melbourne, 3010, Victoria, Australia
bMelbourne Centre for Data Science, The University of Melbourne, Melbourne, 3010, Victoria, Australia
cCentre of Excellence for Biosecurity Risk Analysis, The University of Melbourne, Melbourne, 3010, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christopher M. Baker
Patricia T. Campbell
eMelbourne School of Population and Global Health, The University of Melbourne, Melbourne, 3010, Victoria, Australia
fDepartment of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, 3010, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Patricia T. Campbell
Deborah Cromer
gKirby Institute, University of New South Wales, Sydney, 2052, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Deborah Cromer
Michael J. Lydeamore
hDepartment of Econometrics and Business Statistics, Monash University, Melbourne, 3800, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michael J. Lydeamore
Yasmine McDonough
dPopulation Health & Immunity Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, 3052, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ivo Mueller
dPopulation Health & Immunity Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, 3052, Victoria, Australia
iDepartment of Medical Biology, The University of Melbourne, Melbourne, 3010, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ivo Mueller
Gerard Ryan
eMelbourne School of Population and Global Health, The University of Melbourne, Melbourne, 3010, Victoria, Australia
jTelethon Kids Institute, Nedlands, 6009, Western Australia, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gerard Ryan
Camelia Walker
aSchool of Mathematics and Statistics, The University of Melbourne, Melbourne, 3010, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Camelia Walker
Yingying Wang
eMelbourne School of Population and Global Health, The University of Melbourne, Melbourne, 3010, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natalie Carvalho
eMelbourne School of Population and Global Health, The University of Melbourne, Melbourne, 3010, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Natalie Carvalho
  • For correspondence: tk.le{at}unimelb.edu.au natalie.carvalho{at}unimelb.edu.au j.mcvernon{at}unimelb.edu.au
Jodie McVernon
fDepartment of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, 3010, Victoria, Australia
kVictorian Infectious Diseases Reference Laboratory Epidemiology Unit at the Peter Doherty Institute for Infection and Immunity, The Royal Melbourne Hospital, Melbourne, 3010, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jodie McVernon
  • For correspondence: tk.le{at}unimelb.edu.au natalie.carvalho{at}unimelb.edu.au j.mcvernon{at}unimelb.edu.au
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Following widespread exposure to Omicron variants, COVID-19 has transitioned to endemic circulation. Populations now have diverse infection and vaccination histories, resulting in heterogeneous immune landscapes. Careful consideration of vaccination is required through the post-Omicron phase of COVID-19 management to minimise disease burden. We assess the impact and cost-effectiveness of targeted COVID-19 vaccination strategies to support global vaccination recommendations.

Methods We integrated immunological, transmission, clinical and cost-effectiveness models, and simulated populations with different characteristics and immune landscapes. We calculated the expected number of infections, hospitalisations and deaths for different vaccine scenarios. Costs (from a healthcare perspective) were estimated for exemplar country income level groupings in the Western Pacific Region. Results are reported as incremental costs and disability-adjusted life years averted compared to no additional vaccination. Parameter and stochastic uncertainty were captured through scenario and sensitivity analysis.

Findings Across different population demographics and income levels, we consistently found that annual elder-targeted boosting strategies are most likely to be cost-effective or cost-saving, while paediatric programs are unlikely to be cost-effective. Results remained consistent while accounting for uncertainties in the epidemiological and economic models. Half-yearly boosting may only be cost-effective in higher income settings with older population demographics and higher cost-effectiveness thresholds.

Interpretation The seresults demonstrate the value of continued booster vaccinations to protect against severe COVID-19 disease outcomes across high and middle-income settings and show that the biggest health gains relative to vaccine costs are achieved by targeting older age-groups.

Funding Funded by the World Health Organization.

Research in context

Evidence before this study

Evidence before this study With COVID-19 now globally endemic, populations exhibit varying levels of natural and vaccine-acquired immunity to SARS-CoV-2. With widespread, if variable, immunity resulting in reduced severity of COVID-19 disease, re-evaluation of the ongoing value of vaccination is required. COVID-19 vaccination strategies must consider the cost-effectiveness of gains from vaccination given prior immunity, and in the context of income and health system capacity to manage COVID-19 alongside other pressing concerns.

Few articles examine cost-effectiveness of COVID-19 vaccination strategies in populations with diverse characteristics and waning hybrid immunity, though there is a large body of literature that considers some combination of these elements or focus on one particular country. Consensus is that allocating vaccine doses to older age groups and those at higher risk of severe disease is most beneficial, albeit assuming either only past natural immunity or no waning immunity. These studies have either not included a cost-effectiveness analysis or, where present, have typically assumed a base case zero-vaccination scenario.

Added value of this study

Added value of this study We consider the contemporary situation where populations have varying degrees of hybrid immunity resulting from both prior infection and vaccination, and where the relevant cost-effectiveness analysis considers only future primary and booster doses in the population. We describe multiple demographics, using exemplar ‘older’ and ‘younger’ populations, in conjunction with low to high past vaccination coverage, low to high past natural infection incidence, and low to high income levels. Under these settings, we determine the cost-effectiveness of a range of targeted boosting strategies (who, when, what).

Implications of all the available evidence

Implications of all the available evidence Our study highlights how future COVID-19 booster doses targeted towards older age groups at risk of severe outcomes can be cost-effective or cost-saving in high-income settings with populations that have a higher proportion of individuals at risk. In younger, lower-resourced settings, annual boosting of older age groups may still be cost-effective or cost-saving in some scenarios. We consistently find that pediatric vaccination is not cost-effective. Given the benefits of vaccination, especially to reduce severe disease, we show the importance of ongoing global efforts to provide and equitably distribute vaccines and strengthen adult immunisation programs.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by the World Health Organization. In addition, we would like to acknowledge the support from the Australian Government Department of Foreign Affairs and Trade Indo-Pacific Centre for Health Security (Supporting Preparedness in the Asia-Pacific Region through Knowledge) and the Australian National Health and Medical Research Council (NHMRC) SPECTRUM CRE (GNT1170960). ABH and IM are funded by NHMRC Investigator Grants (2021/GNT2009278 and 2022/GNT2016726 respectively). IM is also supported by NHMRC Principal Research Fellowship (GNT1155075).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

  • ↵† N. Carvalho and J. McVernon should be considered joint senior author.

  • ✉ tk.le{at}unimelb.edu.au (T.P. Le); natalie.carvalho{at}unimelb.edu.au, (N. Carvalho); j.mcvernon{at}unimelb.edu.au (J. McVernon)

Data Availability

All data produced in the present study are available upon reasonable request to the authors. Code is available in the following GitHub repositories: https://github.com/goldingn/neuts2efficacy/ for the immunological model; https://github.com/spectrum-spark/covid_singlestrain_scenarios/tree/singlestrain-paper for the population transmission and clinical pathway models; and https://github.com/spectrum-spark/covid-CEA/ for the cost-effectiveness analysis.

https://github.com/goldingn/neuts2efficacy/

https://github.com/spectrum-spark/covid_singlestrain_scenarios/tree/singlestrain-paper

https://github.com/spectrum-spark/covid-CEA/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted November 15, 2023.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Cost-effective boosting allocations in the post-Omicron era of COVID-19 management
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Cost-effective boosting allocations in the post-Omicron era of COVID-19 management
Thao P. Le, Eamon Conway, Edifofon Akpan, Isobel Abell, Patrick Abraham, Christopher M. Baker, Patricia T. Campbell, Deborah Cromer, Michael J. Lydeamore, Yasmine McDonough, Ivo Mueller, Gerard Ryan, Camelia Walker, Yingying Wang, Natalie Carvalho, Jodie McVernon
medRxiv 2023.11.14.23298536; doi: https://doi.org/10.1101/2023.11.14.23298536
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Cost-effective boosting allocations in the post-Omicron era of COVID-19 management
Thao P. Le, Eamon Conway, Edifofon Akpan, Isobel Abell, Patrick Abraham, Christopher M. Baker, Patricia T. Campbell, Deborah Cromer, Michael J. Lydeamore, Yasmine McDonough, Ivo Mueller, Gerard Ryan, Camelia Walker, Yingying Wang, Natalie Carvalho, Jodie McVernon
medRxiv 2023.11.14.23298536; doi: https://doi.org/10.1101/2023.11.14.23298536

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Health Economics
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)